Business Context and Reporting Period
Aptevo Therapeutics Inc. filed this Form 8-K on July 20, 2017, to report the entry into a Material Definitive Agreement. The registrant is a Delaware corporation focused on therapeutic development.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new strategic collaboration.
Material Changes and Agreement Details
On July 20, 2017, Aptevo Research and Development LLC entered into a Collaboration and Option Agreement with Alligator Bioscience AB. Key terms include:
- Objective: Collaborative development of a lead bispecific antibody candidate targeting 4-1BB (CD137) and a second tumor antigen.
- Scope: Development through the completion of Phase II clinical trials based on an agreed plan and budget.
- Intellectual Property: Joint ownership of IP generated during development, with exceptions for Aptevo's manufacturing and platform technologies.
- Commercialization: Parties intend to seek a third-party partner post-development. Revenue from a partner would be shared equally or in proportion to development costs borne.
- Option: Alligator granted Aptevo a time-limited option to jointly develop a separate bispecific antibody product.
Outlook, Risks, and Contingencies
The agreement includes specific mechanisms for risk management and exit strategies:
- Opt-Out Rights: Either party may terminate without cause at specific development points. The continuing party assumes full development costs and gains exclusive rights, subject to tiered royalties (low to mid-single digits) on net sales if self-commercializing.
- Stage Gates: Automatic termination occurs if agreed technical criteria are not met, unless parties agree to continue.
- Standard Termination: Rights exist for material breach (following a cure period) and insolvency.
Investor Verification Checklist
- Verify the specific budget and cost-sharing structure for the Phase II development plan.
- Confirm the exact timeline for the "time-limited option" to develop the second bispecific antibody.
- Review the full Collaboration Agreement (to be filed as an exhibit to the Q3 2017 Form 10-Q) for detailed royalty tiers and stage gate criteria.
- Assess the impact of potential opt-out scenarios on Aptevo's future cash burn and IP portfolio.